Aarti Drugs Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0efm662c7q9zjbkhlhzpgg86.pdf

Key Takeaways


Volume & Demand Recovery

Patil: "the same thing had happened for metro and ciprofloxacin also in past. We had got antidumping duties for 4, 5 years. And by the next round when it came, we were so profitable that we did not qualify for antidumping duty. So we feel this will turn around."

Greenfield Projects & Backward Integration

Patil: "So right now the situation is such that we are compelled to do. We have already developed technology for that. We have done piloting also for the downstream products. So we are coming up with salicylate block as well very recently in a quarter or two."

Margin Walk & Profitability Bridge


Salicylic Acid: The Contrarian Bet


Formulations & Oncology: The Medium-Term Margin Story


Capex, Capacity & Other Initiatives


Guidance & Commitments

CommitmentSpecificsTimeline
Sayakha utilization ramp50% utilizationMarch–April 2026
Sayakha utilization ramp75% utilizationQuarter following March 2026
Sayakha utilization ramp80%–90% utilizationWithin 12 months
Backward integration for antidiabetic90%–100% captive self-reliance (from ~12% today)Two to three quarters
Salicylic acid plant output800–1,000 metric tonsNext year (FY27)
Antidumping duty applicationFile application against Chinese salicylic acid importsQ1 FY27 or end-Q1 (eligible from April 2026)
Oncology first commercializationFirst product launchedQ4 FY26
Metformin US FDA auditFile DMF, trigger auditComing year
Standalone API gross margin36%FY27
EBITDA margin12%–13% (first target), then 14%–15% steady stateNot dated; conditional on projects running smoothly
FY27 volume growth12%–15%FY27
Capex₹150–₹200 crores per yearNext two years
Salicylate downstream blockCommission dedicated blockA quarter or two

Key Metrics

MetricQ3 FY26
Consolidated revenue₹602.9 cr, up 8% YoY from ₹557.1 cr
Consolidated EBITDA₹56.3 cr, down 10% YoY from ₹62.3 cr
Consolidated EBITDA margin9.3%, vs 12.9% in Q2 FY26
Consolidated PAT₹40.5 cr, up 58% YoY from ₹25.7 cr
Consolidated PAT margin6.7%
Standalone revenue₹530.0 cr, 88% of consolidated revenue
Standalone volume growth7% YoY, with negative rate variance of around 5%
Formulation segment revenue₹76.6 cr, up 58% YoY
Exports share in standalone revenue37%
Exports share in formulation revenue67%
Consolidated gross margin35.9%, impacted by ~1% from inventory sell-down
Sayakha facility utilization~30% in first quarter of operations
Salicylic acid productionAbove 300 tons per month at Tarapur facility
Total consolidated debt~₹540 cr; standalone debt ~₹392 cr
EBITDA drag from Sayakha and salicylic acid plants~₹8.5 cr combined at EBITDA level
Capex guidance₹150 cr to ₹200 cr per year for next 2 years